Dow Jones
37 775,38 +22,07 (+0,06 %) Nasdaq
15 601,50 -81,87 (-0,52 %) Nikkei 225
38 079,70 +117,90 (+0,31 %) EUR/USD
1,0645 -0,0001 (-0,01 %) HANG SENG
16 385,87 +134,03 (+0,82 %) Bitcoin EUR
59 679,91 +2 047,80 (+3,55 %)
Crossject Société Anonyme (ALCJ.PA)
Crossject Société Anonyme
6 Rue Pauline Kergomard
Dijon 21000
France
33 3 80 54 98 50
https://www.crossject.com
Secteur(s): Healthcare
Secteur d’activité: Medical Instruments & Supplies
Employés à temps plein:
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Mr. Patrick Alexandre | Co-Founder, CEO & Chairman of the Executive Board | S.O. | S.O. | S.O. |
| Dr. Isabelle Liebschütz | Chief Quality & Regulatory Officer and Member of Executive Board | S.O. | S.O. | S.O. |
| Mr. Henri de Parseval | COO of Engineering & Industry and Member of Executive Board | S.O. | S.O. | S.O. |
| Mr. Olivier Giré | COO of Specialty Pharma & Member of Executive Board | S.O. | S.O. | S.O. |
Description
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, a needle-free device for patient-side management disorders self-injectables. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. The company was founded in 2001 and is based in Dijon, France.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Crossject Société Anonyme en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..
